Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE PhRMA Issues Program for 21st Century Health Reform in Japan
December 9, 2002
-
ARCHIVE Atol: Net Profits Down 16.3% Despite Higher Sales
December 9, 2002
-
ARCHIVE NanoCarrier, Kirin to Collaborate on Novel Anticancer Agents
December 9, 2002
-
ARCHIVE Bayer AG Actively Seeking Alliance: Mr Wenning
December 9, 2002
-
ARCHIVE Astis: Sales Up 0.9% to \44.7 Bil.
December 9, 2002
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 9, 2002
-
ARCHIVE Sankyo to Spin Off Agricultural Chemicals, Specialty Products
December 9, 2002
-
ARCHIVE Seiwa Sangyo: 4.5% Increase in Sales Boosts Profits
December 9, 2002
-
ARCHIVE Kobayashi Pharma: New Products, Cost-cutting Boost Sales and Profits
December 9, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
December 9, 2002
-
ARCHIVE Sales of Tacrolimus to Reach \100 Bil. Worldwide: Dr Aoki of Fujisawa
December 9, 2002
-
ARCHIVE OTC NEWS IN BRIEF
December 9, 2002
-
ARCHIVE Amarin Targets Major Drug Companies in Japan: Mr Downie
December 9, 2002
-
ARCHIVE Sanki: Net Profits Up 42.4% with 3.1% Rise in Sales
December 9, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
December 9, 2002
-
ARCHIVE 27 Listed Drug Firms: Sales Up 4.1%, Net Profits Down 8.4%
December 9, 2002
-
ARCHIVE Ohki: Profits Leap with 8.6% Rise in Sales
December 9, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
December 9, 2002
-
ARCHIVE Taisho: Sales Flat, Ordinary and Net Profits Slip
December 9, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
December 9, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…